Marabex (MAGE-A3 vaccine) / Turnstone Biologics, AbbVie - LARVOL DELTA

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov) - P1/2 | N=56 | Active, not recruiting | Sponsor: Canadian Cancer Trials Group | Trial completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAGEA3 • PD-L1

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov) - P1/2 | N=56 | Active, not recruiting | Sponsor: Canadian Cancer Trials Group | Trial completion date: Dec 2023 ➔ Dec 2024

Metastases • Trial completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAGEA3 • PD-L1

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov) - P1/2 | N=56 | Active, not recruiting | Sponsor: Canadian Cancer Trials Group | Trial completion date: Jun 2023 ➔ Dec 2023

Metastases • Trial completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAGEA3 • PD-L1

Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214. (ASCO 2017) - P1/2; "AdMA3 prime followed by MG1MA3 OV boost is feasible with a defined RP2DL, and capable of inducing potent anti-tumour immune response. Alternate schedules will be evaluated."

Clinical • Oncolytic virus • P1 data • Biosimilar • Oncology • Renal Disease

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov) - P1/2 | N=56 | Active, not recruiting | Sponsor: Canadian Cancer Trials Group | Trial completion date: Dec 2022 ➔ Jun 2023

Metastases • Trial completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAGEA3 • PD-L1

Pelican: MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - P1b; N=0; Withdrawn; Sponsor: Turnstone Biologics, Corp.; N=40 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Combination therapy • Enrollment change • Trial withdrawal • Immune Modulation • Inflammation • Melanoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • MAGEA3

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients (clinicaltrials.gov) - P1/2; N=16; Completed; Sponsor: Turnstone Biologics, Corp.; Active, not recruiting ➔ Completed; N=75 ➔ 16; Trial completion date: Aug 2021 ➔ May 2020

Clinical • Combination therapy • Enrollment change • Trial completion • Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR

Pelican: MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - P1b; N=40; Not yet recruiting; Sponsor: Turnstone Biologics, Inc.; Initiation date: Jan 2019 ➔ Jan 2020

Clinical • Combination therapy • Trial initiation date

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients (clinicaltrials.gov) - P1/2; N=75; Suspended; Sponsor: Turnstone Biologics, Inc.; Recruiting ➔ Suspended

Clinical • Combination therapy • Trial suspension

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients (clinicaltrials.gov) - P1/2; N=75; Active, not recruiting; Sponsor: Turnstone Biologics, Inc.; Suspended ➔ Active, not recruiting

Clinical • Combination therapy • Enrollment closed